Walleye Capital
RCUS icon

Walleye Capital’s Arcus Biosciences RCUS Stock Holding History

Walleye Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,900
Closed -$141K – 4883
2025
Q4 		$141K Buy
+5,900
New +$120K ﹤0.01% 3718
2024
Q2 		– Sell
-1,000
Closed -$18.9K – 5925
2024
Q1 		$18.9K Sell
1,000
-1,100
-52% -$19K ﹤0.01% 4945
2023
Q4 		$40.1K Sell
2,100
-2,300
-52% -$36.8K ﹤0.01% 4354
2023
Q3 		$79K Hold
4,400
– – ﹤0.01% 4035
2023
Q2 		$89.4K Hold
4,400
– – ﹤0.01% 3472
2023
Q1 		$80.3K Buy
+4,400
New +$84.1K ﹤0.01% 3040

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Walleye Capital's RCUS Position: Q1 2026 in Review

Walleye Capital sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 1 share — an estimated $24 sold.

Walleye Capital first reported a position in RCUS in Q3 2020 and held it in 11 quarters. The position peaked at $7.58M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Walleye Capital reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1 Arcus Biosciences share in Q1 2026, an estimated $24.
  • Walleye Capital first reported a position in Arcus Biosciences in Q3 2020 and held it in 11 quarters.
  • Walleye Capital's Arcus Biosciences position peaked at $7.58M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.